• Circulating microRNAs may predict breast cancer treatment response

    on January 12th, 2017
    AT SABCS 2016 SAN ANTONIO (FRONTLINE MEDICAL NEWS) – Circulating microRNAs may predict treatment response in HER2-positive breast cancer patients treated with neoadjuvant therapy, according to findings from the randomized phase III NeoALTTO trial. Specifically, four circulating tumor microRNA sign[...]
  • 177Lu-Dotatate for advanced midgut neuroendocrine tumors

    on January 12th, 2017
    FROM THE NEW ENGLAND JOURNAL OF MEDICINE 177Lu-Dotatate, a radionuclide related to octreotide, reduced the risk of disease progression or death by 79% in a phase III trial involving 229 adults with advanced, progressive midgut neuroendocrine tumors, investigators reported in the New England Journal [...]
  • Ibrutinib continues to wow in CLL/SLL

    on January 11th, 2017
    AT ASH 2016 SAN DIEGO (FRONTLINE MEDICAL NEWS) – More than 90% of the first patients with previously untreated chronic lymphocytic leukemia who received ibrutinib in an early study are alive and without disease progression 5 years later, investigators reported. Among 31 treatment-naive patients wi[...]
  • CTCs help predict breast cancer outcomes in neoadjuvant setting

    on January 9th, 2017
    AT SABCS 2016 SAN ANTONIO (FRONTLINE MEDICAL NEWS) – Circulating tumor cells are a useful prognostic biomarker in early breast cancer patients treated with neoadjuvant chemotherapy, according to findings from an international meta-analysis of individual patient data. The cells (CTCs), which can be[...]
  • Adjuvant chemo prolonged survival after radical nephroureterectomy

    on January 9th, 2017
    FROM JOURNAL OF CLINICAL ONCOLOGY Adjuvant chemotherapy prolonged survival after radical nephroureterectomy by nearly a year, compared with observation alone, among patients with locally advanced or positive regional lymph node upper tract urothelial carcinoma, researchers reported. After a median f[...]
  • Sorafenib survival benefit in HCC depends on etiology

    on January 6th, 2017
    FROM THE JOURNAL OF CLINICAL ONCOLOGY The impact of sorafenib in treating patients with advanced hepatocellular cancer may be dependent on their hepatitis status, according to a meta-analysis of patient-level data from three large prospective clinical trials using sorafenib as the control treatment.[...]
  • Gastric cancer yields to growth hormone antagonist in lab

    on January 6th, 2017
    FROM PNAS It sounds counterintuitive, but targeting a neuropeptide hormone produced in the hypothalamus may be an effective strategy for treating gastric cancer, the second most common cause of cancer deaths worldwide, investigators from China and the United States contend. Growth hormone–releasin[...]
  • In NSCLC, delayed chemo yields survival benefit comparable to early chemo

    on January 6th, 2017
    FROM JAMA ONCOLOGY Patients with non–small-cell lung cancer (NSCLC) for whom adjuvant chemotherapy must be delayed for as long as 18 weeks have mortality outcomes that are no worse than those of patients who start chemotherapy soon after surgery, and those who undergo delayed chemotherapy have a s[...]
  • Adding epoetin alfa to lenalidomide boosted myelodysplastic syndrome responses

    on January 5th, 2017
    AT ASH 2016 SAN DIEGO (FRONTLINE MEDICAL NEWS) – Dual therapy with lenalidomide and epoetin alfa was safe and led to freedom from transfusion significantly more often than lenalidomide alone in patients with erythropoietin-refractory, lower-risk, non-del(5q) myelodysplastic syndromes, according to[...]
  • Daratumumab combo holds up across POLLUX myeloma subgroups

    on January 5th, 2017
    AT ASH 2016 SAN DIEGO (FRONTLINE MEDICAL NEWS) – Adding daratumumab (D) to lenalidomide and dexamethasone (Rd) significantly improved outcomes in relapsed and refractory multiple myeloma, even when patients had previously received lenalidomide, were refractory to bortezomib, or had high-risk tumor[...]
  • Neoadjuvant AI plus Ki67 info could deescalate adjuvant breast cancer treatment

    on January 4th, 2017
    FROM THE JOURNAL OF CLINICAL ONCOLOGY Triage to chemotherapy using a Ki67-based Preoperative Endocrine Prognostic Index (PEPI), which also integrates residual disease burden, appears useful for deescalating adjuvant treatment after neoadjuvant aromatase inhibitor (AI) therapy for breast cancer, inve[...]
  • Gene, risk signatures could predict PARP inhibitor response in breast cancer

    on January 4th, 2017
    AT SABCS 2016 SAN ANTONIO (FRONTLINE MEDICAL NEWS) – PARPi 7, BRCAness, and MammaPrint high1/(ultra)high2 signatures could help predict response to combination therapy with the poly ADP ribose polymerase (PARP) inhibitors veliparib and carboplatin among high-risk breast cancer patients and thereby[...]
  • FOUND IN TRANSLATION Minimal nomenclature and maximum sensitivity complicate MRD measures

    on December 22nd, 2016
    In hematologic malignancies, there is a deep and direct connection between each individual patient, that patient’s symptoms, the visible cells that cause the disease, and the direct measurements and assessments of those cells. The totality of these factors helps to determine the diagnosis and trea[...]
Back to top